文献速递前列腺癌

177Lu-PNT2002新辅助联合SBRT治疗寡复发前列腺癌的LUNAR试验二次分析

177Lu-Prostate-specific Membrane Antigen Prior to Stereotactic Ablative Radiotherapy in Oligorecurrent Prostate Cancer: Secondary and Exploratory End Point Results from the Randomized Phase 2 LUNAR Trial.
PubMed 文献 · Eur Urol · 2026-10-12

LUNAR 2期随机试验先前显示,在寡复发激素敏感前列腺癌(orHSPC)中,SBRT前新辅助177Lu-PNT2002显著改善无进展生存期(PFS)。本次报告延长随访后的疗效与安全性更新:92例患者随机1:1接受单纯SBRT或两周期177Lu-PNT2002后SBRT,中位随访31.9个月,177Lu-PNT2002组PFS和激素治疗-free生存(HT-FS)显著改善,未观察到新安全性信号。

要点

  • SBRT前新辅助177Lu-PNT2002显著改善orHSPC患者的PFS(中位17.6 vs 7.4个月;HR 0.38)。
  • HT-FS亦显著改善(HR 0.57),延长随访未发现新安全性信号。
  • 探索性终点poly-PFS、CRFS、CT-PFS数值改善,但为假设生成性证据。

核心结论

  • 延长随访后,SBRT前新辅助177Lu-PNT2002在orHSPC中产生持久的PFS和HT-FS改善。

研究设计与样本

  • 2期随机LUNAR试验,92例PSMA PET/CT检测的orHSPC患者(1-5个可SBRT转移灶)随机1:1接受单纯SBRT(n=47)或两周期177Lu-PNT2002后SBRT(n=45)。

主要发现

  • 中位随访31.9个月,177Lu-PNT2002组PFS显著优于单纯SBRT(中位17.6 vs 7.4个月;HR 0.38,95%CI 0.23-0.61;p<0.001)。
  • HT-FS显著改善(HR 0.57,95%CI 0.34-0.95;p=0.03)。
  • 探索性分析:poly-PFS(HR 0.28,95%CI 0.08-1.03;p=0.04)、CRFS(HR 0.13,95%CI 0.02-1.10;p=0.03)、CT-PFS(HR 0.46,95%CI 0.19-1.09;p=0.07)。
  • 未观察到新安全性信号。

临床怎么用

  • 对于PSMA PET/CT检测的寡复发激素敏感前列腺癌患者,可考虑SBRT前新辅助177Lu-PNT2002以延长PFS和推迟激素治疗。
  • 探索性终点改善提示联合 Radioligand therapy 可能改变疾病轨迹,但需进一步验证。

局限性

  • poly-PFS、CRFS和CT-PFS为探索性终点,证据为假设生成性。
  • 2期试验样本量有限(92例),需更大规模研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The phase 2 randomized LUNAR trial previously demonstrated that neoadjuvant 177Lu-PNT2002 before stereotactic body radiotherapy (SBRT) significantly improved progression-free survival (PFS) in patients with oligorecurrent hormone-sensitive prostate cancer (orHSPC). We report updated efficacy and safety outcomes with extended follow-up. Patients with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT)-detected orHSPC and one to five metastatic lesions amenable to SBRT were randomized 1:1 to SBRT alone or two cycles of neoadjuvant 177Lu-PNT2002 followed by SBRT. The primary end point was PFS, defined as new lesions on PSMA PET/CT, initiation of salvage hormonal therapy, or death. Secondary end points included hormonal therapy-free survival (HT-FS) and 24-mo progression-free status. Exploratory end points included polymetastatic PFS (poly-PFS), castration-resistant disease-free survival (CRFS), and conventional imaging progression-free survival (CT-PFS). Between September 2022 and November 2023, 92 patients were randomized to SBRT alone (n = 47) or 177Lu-PNT2002 plus SBRT (n = 45). At a median follow-up of 31.9 mo, 177Lu-PNT2002 significantly improved PFS (median 17.6 vs 7.4 mo; hazard ratio [HR] 0.38, 95% confidence interval [CI] = 0.23-0.61; p < 0.001) and HT-FS (HR 0.57, 95% CI = 0.34-0.95; p = 0.03). Exploratory analyses demonstrated improved poly-PFS (HR 0.28, 95% CI = 0.08-1.03; p = 0.04), CRFS (HR 0.13, 95% CI = 0.02-1.10; p = 0.03), and CT-PFS (HR 0.46, 95% CI = 0.19-1.09; p = 0.07). No new safety signals were observed. With extended follow-up, neoadjuvant 177Lu-PNT2002 before SBRT produced durable improvements in PFS and HT-FS. While poly-PFS, CRFS, and CT-PFS were exploratory end points, their improvement provides hypothesis-generating evidence that the addition of radioligand therapy to SBRT may alter disease trajectory beyond delaying PSMA PET/CT-detected recurrence.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Kishan AU, Wilhalme H, Felix C, et al. 177Lu-Prostate-specific Membrane Antigen Prior to Stereotactic Ablative Radiotherapy in Oligorecurrent Prostate Cancer: Secondary and Exploratory End Point Results from the Randomized Phase 2 LUNAR Trial. Eur Urol. 2026. PMID: 42864228. doi:10.1016/j.eururo.2026.09.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。